利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.029 秒)

    Opioid formulations having extended controlled release
    1.
    发明公开
    Opioid formulations having extended controlled release 失效
    阿维西亚形容词Veriägergergesteuerter Wirkstoffabgabe

    公开(公告)号：EP2263673A1

    公开(公告)日：2010-12-22

    申请号：EP10178499.9

    申请日：1994-06-22

    申请人： EURO-CELTIQUE S.A.

    发明人： Sackler, Richard S. ,  Oshlack, Benjamin ,  Chasin, Mark ,  Goldenheim, Paul ,  Kaiko, Robert ,  Pedi, Frank Jr.

    IPC分类号： A61K31/485 ,  A61K9/50 ,  A61K9/16 ,  A61K9/20

    CPC分类号： A61K9/1635 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2081 ,  A61K9/2095 ,  A61K9/2866 ,  A61K9/5078 ,  A61K31/485 ,  A61K31/522

    摘要： A solid, controlled release, oral dosage form, the dosage form comprising an analgesically effective amount of an opioid analgesic or a salt thereof, coated with a controlled-release coating or in a controlled-release matrix, wherein the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C is from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours and greater than 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid obtained in-vivo occurs from about 2 to about 6 hours after administration of the dosage form.

    摘要翻译： 一种固体，控制释放的口服剂型，所述剂型包含镇痛有效量的阿片类镇痛剂或其盐，涂覆有控释包衣或控释基质，其中体外溶出速率 当在37℃下以900rpm含水缓冲液（pH值在1.6和7.2之间）以100rpm测量时，剂型为1小时后释放的约12.5％至约42.5％（重量）的阿片样物质， 2小时后约25％〜约65％（重量）的阿片样物质释放，4小时后释放的约45％〜约85％（重量）阿片样物质，8小时后释放大于60重量％的阿片样物质， 体外释放速率基本上不依赖于pH，并且被选择为使得在给药剂型后约2至约6小时内在体内获得的所述阿片样物质的峰值血浆水平发生。

    Controlled-release formulations coated with aqueous dispersions of ethylcellulose
    4.
    发明公开
    Controlled-release formulations coated with aqueous dispersions of ethylcellulose 失效
    涂有乙基纤维素的水分散体具有受控释放制剂

    公开(公告)号：EP1475085A1

    公开(公告)日：2004-11-10

    申请号：EP04018825.2

    申请日：1994-06-14

    申请人： Euro-Celtique S.A.

    发明人： Oshlack, Benjamin ,  Chasin, Mark ,  Pedi, Frank Jr.

    IPC分类号： A61K9/50 ,  A61K9/28 ,  A61K31/485

    CPC分类号： A61K9/167 ,  A61K9/2866 ,  A61K9/5078 ,  A61K31/522

    摘要： The invention concerns controlled release oxycodone dosage forms comprising a multiparticulate system substrate comprising an effective amount of oxycodone salt, the substrate being coated with an aqueous dispersion of at least one hydrophobic polymer, whereby the coating provides controlled release and the release is further influenced by the addition of at least one release-modifying agent, whereby the dosage forms comprise the cured, coated substrate and provide a therapeutic effect for at least 12 hours when administered to a patient.

    摘要翻译： 本发明涉及一种控制释放的羟考酮的剂型包括含有有效量的羟考酮的盐的多颗粒系统的基板，在基板上涂覆有在至少一种疏水性聚合物的wässrige分散体，由此所述涂层提供控制释放和剥离进一步通过影响 加入至少一种释放改性剂，由此所述剂型包含固化的，涂覆的基材，并且当施用于患者为至少12小时提供治疗效果的。

    Controlled-release formulations coated with aqueous dispersions of ethylcellulose
    9.
    发明公开
    Controlled-release formulations coated with aqueous dispersions of ethylcellulose 失效
    涂有乙基纤维素的水分散体具有受控释放制剂

    公开(公告)号：EP2018852A1

    公开(公告)日：2009-01-28

    申请号：EP08162715.0

    申请日：1994-06-14

    申请人： EURO-CELTIQUE S.A.

    发明人： Oshlack, Benjamin ,  Chasin, Mark ,  Pedi, Frank Jr.

    IPC分类号： A61K9/16 ,  A61K31/485 ,  A61P25/04

    CPC分类号： A61K9/167 ,  A61K9/2866 ,  A61K9/5078 ,  A61K31/522

    摘要： The invention concerns controlled release oxycodone dosage forms comprising a multiparticulate system substrate comprising an amount of an oxycodone salt, the substrate being coated with an aqueous dispersion of at least one hydrophobic polymer, whereby the coating provides controlled release, the substrate including an additional dose of an oxycodone salt included in either the controlled release coating or in an additional overcoating coated on the outer surface of the controlled release coating, whereby the dosage forms, comprising the cured, coated substrate, comprise an effective amount of an oxycodone salt and provide a therapeutic effect for at least 12 hours when administered to a patient.